Mayinglong Pharmaceutical Group Co., LTD. Stock price

Equities

600993

CNE000001HN2

Pharmaceuticals

End-of-day quote Shanghai S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
22.18 CNY +1.09% Intraday chart for Mayinglong Pharmaceutical Group Co., LTD. -3.23% -8.27%
Sales 2021 3.39B 469M Sales 2022 3.53B 489M Capitalization 9.74B 1.35B
Net income 2021 465M 64.39M Net income 2022 479M 66.32M EV / Sales 2021 2.92 x
Net cash position 2021 2.5B 346M Net cash position 2022 2.67B 369M EV / Sales 2022 2 x
P/E ratio 2021
26.6 x
P/E ratio 2022
20.4 x
Employees 3,241
Yield 2021
1.22%
Yield 2022
1.55%
Free-Float 61.06%
More Fundamentals * Assessed data
Dynamic Chart
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hangzhou Yunbai Pharmaceutical Technology Co., Ltd. agreed to acquire 86.816% of stake in Shenzhen Daphne Pharmaceautical Co.,Ltd from from Mayinglong Pharmaceutical Group Co., LTD., Huayi Development Co., Ltd., China Bao An Co., Ltd and Guofa Jianfu Industrial Co., Ltd. for approximately CNY 260 million. CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020 CI
More news
1 day+1.09%
1 week-3.23%
Current month-5.21%
1 month-3.06%
3 months-8.20%
6 months-3.77%
Current year-8.27%
More quotes
1 week
21.70
Extreme 21.7
22.55
1 month
21.70
Extreme 21.7
24.55
Current year
20.20
Extreme 20.2
24.83
1 year
20.20
Extreme 20.2
32.20
3 years
17.69
Extreme 17.69
33.54
5 years
14.24
Extreme 14.24
33.54
10 years
11.54
Extreme 11.5385
40.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 -
Director of Finance/CFO 42 19-05-27
Chairman 59 -
Members of the board TitleAgeSince
Chief Executive Officer 46 -
Chairman 59 -
Director/Board Member 60 23-06-12
More insiders
Date Price Change Volume
24-03-28 22.18 +1.09% 3,616,900
24-03-27 21.94 -0.68% 3,420,247
24-03-26 22.09 +0.32% 3,206,615
24-03-25 22.02 -1.74% 3,933,338
24-03-22 22.41 -2.23% 4,474,233

End-of-day quote Shanghai S.E., March 27, 2024

More quotes
Mayinglong Pharmaceutical Group Co., Ltd. is a China-based company, principally engaged in pharmaceutical production, retailing and wholesaling businesses. The Company's pharmaceutical products are classified as drugs for hemorrhoid, including diosmin tablets, suppositories, pastes and granules, among others; drugs for cough, including levodropropizine oral solution and compound glycyrrhiza oral solution, as well as drugs for skin injuries, including products such as erythromycin ointment. The Company also provides specialty drugs. The Company is also engaged in the production and distribution of eye cream products with the brand named Mayinglong BaBao, as well as the provision of hospital clinical service. The Company distributes its products mainly in domestic markets.
Calendar
More about the company
  1. Stock
  2. Equities
  3. Stock Mayinglong Pharmaceutical Group Co., LTD. - Shanghai S.E.